Essential Thrombocythemia, Polycythemia Vera
Conditions
Keywords
Polycythaemia Vera, Polycythemia Vera, Essential Thrombocythaemia, Essential Thrombocythemia, HDAC-inhibitor, Haematology, Hematology, Haematological disorder, Haematological disease, Hematological disorder, Hematological disease
Brief summary
The aim of the present study is to evaluate the efficacy and safety of MK-0683 in the treatment of PV and ET. This agent has most recently been shown to be a potent inhibitor of the autonomous proliferation of haematopoietic cells of PV and ET patients carrying the JAK2 V617F mutation. Accordingly, it may be anticipated that MK-0683 - by decreasing the JAK2 allele burden - may influence clonal myeloproliferation and in vivo granulocyte, platelet and endothelial activation , which are considered to be major determinants of morbidity and mortality ( thrombosis, bleeding, extramedullary haematopoiesis , myelofibrosis ) in these disorders. The effects of MK-0683 at the molecular level will be studied by global/ focused gene expression profiling, epigenome profiling and proteomics.
Interventions
DRUGHDAC inhibitor (MK-0683)
400 mg once daily for 6 months
Sponsors
Copenhagen University Hospital at Herlev
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patient \> 18 years of age AND * A confirmed diagnosis of PV AND * Biochemical evidence of active disease as defined by: * a need for phlebotomy within last 3 months * a leukocyte count \> 10 x 10\^9/L in the absence of infection or inflammation (normal CRP) and/or (PV/ET) * a platelet count \> 450 x 10\^9/L in the absence of infection or inflammation (normal CRP)(PV/ET) OR * Male or female patient \> 18 years of age AND * A confirmed diagnosis of ET AND * Biochemical evidence of active disease as defined by \*a platelet count \> 450 x 10\^9/L in the absence of infection or inflammation Inclusion Criteria for both PV and ET: * Newly diagnosed or previously treated patient in chronic phase OR * Advanced phase PV or ET as defined by blasts of \> 1 x 10\^9/L in the peripheral blood and/or white cell count \> 30 x 10\^9/L OR * Resistant or refractory PV or ET as defined by haemoglobin \< 10.5 gm/dl with a platelet count \> 600 x 10\^9/L on current therapy OR * Cycling platelet counts on therapy OR * Intolerant to other therapies defined by patients with PV or ET who have side effects on current therapies preventing continuation (leg ulcers on hydroxycarbamide, unacceptable fatigue etc on interferon)
Exclusion criteria
* A platelet count \> 1500 x 10\^9/L (a need for cytoreduction in platelet count) * Patients of childbearing potential without a negative pregnancy test prior to initiation of study drug * Women who are breast feeding * Males and females not using contraceptives if sexually active. * EGOC Performance status Score \> or = 3 * Serum creatinine more than 2 x's teh ULN * Total serum bilirubin more than 1.5 x's the ULN * Serum AST/ALT more than 3 x's the ULN * Interferon alpha within 1 week of day 1 * Hydroxycarbamide within 1 week of day 1 * Anagrelide within 1 week of day 1 * Valproic acid (as an anticonvulsant) within 28 days of day 1 * Any other investigational drug within 28 days of day 1 * Active HIV, HBV or HCV infection * Any serious concomitant disease or circumstances that could limit compliance with the study, including but not limited to the following: CTCAE grade 3-4 cardiac general & arrhythmia, or psychiatric or social conditions that may interfere with patient compliance. * Any prior malignancy with the exception of cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or other localized malignancy that has undergone potentially curative therapy with no evidence of that disease for five years, and who is deemed to be at low risk for recurrence by his/her treating physician. * Patient has a known allergy or hypersensitivity to study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the efficacy of study drug (MK-0683) in the treatment of patients with PV and ET. | one year |
Secondary
| Measure | Time frame |
|---|---|
| To study changes in bone marrow morphology before and after treatment with study drug. | one year |
Countries
Denmark, Netherlands, Sweden, United Kingdom
Outcome results
None listed